Earlier Disclosure of Blood-Based Biomarkers Enhances Diagnostic Certainty and Clinical Management in Cognitive Disorders: A Review of a Recent Randomized Clinical Trial
Posted inClinical Updates Neurology news Pathology & Lab Medicine

Earlier Disclosure of Blood-Based Biomarkers Enhances Diagnostic Certainty and Clinical Management in Cognitive Disorders: A Review of a Recent Randomized Clinical Trial

Early disclosure of plasma p-tau217 and NfL biomarkers significantly improves diagnostic confidence and clinical decisions in cognitive decline without increasing emotional distress, supporting their integration into routine memory clinic care.
Discriminating Prion Diseases from Alzheimer’s Disease Using Plasma Biomarkers: The Crucial Role of NfL/p-tau217 Ratio
Posted inNeurology news Pathology & Lab Medicine/Bệnh học

Discriminating Prion Diseases from Alzheimer’s Disease Using Plasma Biomarkers: The Crucial Role of NfL/p-tau217 Ratio

Plasma phosphorylated tau biomarkers overlap in Alzheimer’s and prion diseases, risking diagnostic confusion. The NfL/p-tau217 ratio emerges as an accurate plasma biomarker to distinguish prion diseases from Alzheimer’s, improving diagnostic precision and guiding appropriate clinical management.
Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study
Posted inNeurology news Psychiatry

Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study

This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention's feasibility and safety, providing crucial effect size estimates for future neuroprotective research.